Vyleesi vs PT-141 comes down to FDA status: both contain bremelanotide, but only Vyleesi is FDA-approved for human use in the United States.
Vyleesi and PT-141 are not two competing drugs — they are two labels for the same molecule, bremelanotide. Vyleesi is the FDA-approved brand-name autoinjector for premenopausal women with hypoactive sexual desire disorder (HSDD), while PT-141 is the original research code and the name still used for non-approved bremelanotide sold as a research chemical. The most important difference between them is regulatory status and manufacturing oversight, not the active ingredient.
What Vyleesi Actually Is
Vyleesi (bremelanotide injection) was approved by the FDA in June 2019 for acquired, generalized HSDD in premenopausal women. It ships as a single-use subcutaneous autoinjector that delivers 1.75 mg of bremelanotide into the thigh or abdomen.
- Timing: injected at least 45 minutes before anticipated sexual activity.
- Frequency: no more than one dose in 24 hours, and no more than eight doses per month.
- Mechanism: a melanocortin receptor agonist that acts on the central nervous system rather than on blood flow.
Vyleesi is not a daily pill and it is not taken on a schedule. It is used as needed, and the monthly cap exists because the drug's side-effect profile — particularly nausea and blood pressure changes — makes very frequent use impractical.
What People Mean by PT-141
PT-141 was Palatin Technologies' internal development code for bremelanotide, long before the brand name Vyleesi existed. In the research-peptide market, PT-141 is still the common label, and the product is usually lyophilized powder that the buyer reconstitutes with bacteriostatic water.
That distinction matters. Research-grade PT-141 is not FDA-approved for human use, is not manufactured under pharmaceutical sterility standards, and rarely comes with independent purity verification. A seller's Certificate of Analysis is not the same thing as FDA-reviewed manufacturing.
Bremelanotide has been studied in both men and women, and a large share of informal PT-141 use is off-label for male libido — an indication the FDA has never approved.
Vyleesi vs PT-141 Side by Side
| Factor | Vyleesi | PT-141 (research grade) |
|---|---|---|
| Active ingredient | Bremelanotide | Bremelanotide |
| FDA status | Approved for HSDD in premenopausal women | Not approved for human use |
| Form | Single-use 1.75 mg autoinjector | Lyophilized powder, typically reconstituted by the buyer |
| Typical reported dose | 1.75 mg subcutaneous | 1.75–2 mg subcutaneous in informal reports |
| Prescription required | Yes | No — sold as "not for human consumption" |
| Quality oversight | FDA-inspected manufacturing | Usually unverified |
| Insurance coverage | Sometimes covered by commercial plans | Never covered |
Where the Differences Actually Matter
Regulation and quality control
Vyleesi is produced in FDA-inspected facilities, and every batch must meet pharmaceutical quality standards for potency and sterility. Research-grade PT-141 carries no equivalent guarantee, which means dose accuracy and sterility depend entirely on the supplier.
Delivery: injection or nasal spray
Vyleesi is only sold as an injection. When people weigh pt-141 nasal spray vs injection, the key fact is that an intranasal bremelanotide product was submitted to the FDA in the late 2000s and was not approved, largely because of transient blood pressure elevations seen in trials. An injection delivers a predictable dose, while a homemade or compounded nasal spray does not.
Cost and access
Vyleesi carries a high list price per autoinjector, though commercial insurance and manufacturer savings programs reduce the out-of-pocket cost for some patients. Research-grade PT-141 is often cheaper per milligram, but no part of that purchase is covered by insurance and the buyer absorbs all of the risk.
Side Effects and Safety Considerations
Nausea is the most commonly reported side effect of bremelanotide, affecting roughly 40% of participants in Vyleesi's clinical trials. Flushing, headache, injection-site reactions, and vomiting are also common.
The more serious concern is a temporary rise in blood pressure that peaks a few hours after dosing. Bremelanotide is contraindicated in people with uncontrolled hypertension or known cardiovascular disease. Anyone with a history of heart or blood pressure problems should speak with a healthcare professional before using it in any form.
People comparing vyleesi vs addyi should note that Addyi (flibanserin) is an oral daily medication with a different mechanism, a different side-effect profile, and specific alcohol restrictions.
Questions People Ask Most
"How long does pt-141 last" is one of the most common questions about the compound. Reported effects typically begin within 30 to 60 minutes and fade over several hours, though individual responses vary and published data on real-world duration is limited.
Questions about where to buy pt-141 usually lead to research-chemical vendors selling powder labeled for laboratory use only. Bremelanotide is a prescription drug in the United States, so supplying it for human consumption without approval is illegal, and the buyer has no way to confirm what is actually in the vial.
Bottom Line
Vyleesi and PT-141 deliver the same active molecule, but they are not interchangeable products. Vyleesi is an FDA-approved, pharmacy-grade treatment with defined dosing and monitoring. PT-141 is a research label with none of those safeguards. If you are considering bremelanotide for HSDD or for any off-label reason, the safer path is a conversation with a licensed clinician rather than a research supplier.
Frequently Asked Questions
Is PT-141 the same thing as Vyleesi?
Yes. Both contain the active ingredient bremelanotide, a melanocortin receptor agonist. Vyleesi is the FDA-approved brand-name autoinjector approved in 2019 for hypoactive sexual desire disorder in premenopausal women, while PT-141 is the older research code and the name used for non-approved bremelanotide sold as a research chemical.
Is Vyleesi approved for men?
No. Vyleesi is FDA-approved only for acquired, generalized hypoactive sexual desire disorder in premenopausal women. Bremelanotide has been studied in men, but the FDA has not approved it for any male indication, so use in men is off-label and requires a prescriber's judgment.
Is it legal to buy PT-141 online in the United States?
Bremelanotide is a prescription-only drug in the United States, so selling it for human use without FDA approval is illegal. Most vendors label PT-141 powder as a research chemical "not for human consumption," which shifts all legal and safety risk to the buyer. Purity and sterility of those products are generally unverified.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.